The DOI matches its Crossref record.
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY: 4. APPLICATIONS TO PLANNING AND INTERPRETATION OF CLINICAL THERAPEUTIC TRIALS
Abstract
We used hypothetical entry criteria typical of those used in clinical therapeutic trials to determine the patients who would have been eligible among those followed in a clinic-based study of multiple sclerosis (MS) in London, Ontario, between 1972 and 1984. For these patients, we determined the observed frequency of deterioration by 1 point on the disability status scale (DSS) of Kurtzke, which is the most feasible and frequently used endpoint in clinical trials. We calculated the number of patients required for a randomized clinical trial to detect a significant result (alpha = 0.05) with 80% or 90% power based on the observed rate of deterioration. To assess the linearity of the DSS, we determined the frequency of progression and staying time at each level of the DSS. Overall the frequency of progression was lower and the staying times were longer at higher levels of disability. There was considerable intrapatient as well as interpatient variation in staying time. These data have major implications for the design and conduct of clinical therapeutic trials in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Self-citationEbers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Self-citationDevelopment of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. R. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,190
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Self-citationCNS immune privilege: hiding in plain sight
Carson, M. J., Doose, J. M., Melchior, B., Schmid, C. D., & Ploix, C. C. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00441.x · Cited by 795
How patients with multiple sclerosis acquire disability
Lublin, F. D., Häring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., et al. (2022) · Brain · doi:10.1093/brain/awac016 · Cited by 549
“6 describes unequal stay times at different values of the 23 EDSS based on the full dataset.(21) 24”
Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Self-citationNatural history of multiple sclerosis
Weinshenker, B. G. (1994) · Annals of Neurology · doi:10.1002/ana.410360704 · Cited by 405
Self-citationHohol, M. J., Orav, E. J., & Weiner, H. L. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500508 · Cited by 369
Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients
Río, J., Nos, C., Tintoré, M., Téllez, N., Galán, I., Pelayo, R., Comabella, M., & Montalban, X. (2006) · Annals of Neurology · doi:10.1002/ana.20740 · Cited by 327
The Natural History of Multiple Sclerosis
Weinshenker, B. G. (1995) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30064-1 · Cited by 313
Self-citationCohen, J. A., Reingold, S. C., Polman, C. H., & Wolinsky, J. S. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70059-5 · Cited by 233
Age Related Multiple Sclerosis Severity Score: Disability ranked by age
Manouchehrinia, A., Westerlind, H., Kingwell, E., Zhu, F., Carruthers, R., Ramanujam, R., Ban, M., Glaser, A., Sawcer, S., Tremlett, H., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690618 · Cited by 174
Metadata
- Authors
- WEINSHENKER, B. G., RICE, G. P. A., NOSEWORTHY, J. H., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1991
- Volume
- 114
- Issue
- 2
- Pages
- 1057-1067
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1979835871
- Cited by
- 175
- References
- 0
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.